Bristol-Myers Squibb (BMY) said Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency's has recommended the approval of repotrectinib to treat certain patients with advanced non-small cell lung cancer and advanced solid tumors.
The recommendation was based on two trials, in which repotrectinib demonstrated "clinically meaningful" response rates and a "well characterized" safety profile, Bristol-Myers said.
The European Commission will review the committee's recommendation, with a final approval decision expected in January 2025.
Price: 54.52, Change: +0.20, Percent Change: +0.37
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments